Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma - Wikidata - awgldk - TriplyDB

Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma

Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma

http://www.wikidata.org/entity/Q26797643

about

Hepatic resection beyond barcelona clinic liver cancer indication: When and how Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy.Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and 18 F-fluoro-2-deoxyglucose positron emission tomography.Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data.Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.

P2860

Q26751300-DBE1306F-1FD5-4E53-A7F5-588F0F67BE7A Q33699349-FE30AC67-6E75-427F-B4EB-08D9AFD0BEC5 Q39225076-85996A5C-7900-412E-B988-16C1234582CF Q39458547-975E9D76-DFE5-4FAA-B5ED-4AB13F468A3C Q42169289-5D76DFB9-03D0-4D1D-9E11-6EDBCD51A14B Q47100137-289283A0-E161-423C-A23F-DE5892B63152 Q53573051-03AADB7E-E8B8-42E1-81BA-69095BABD197

P2860

Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma

http://www.wikidata.org/entity/Q26797643

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Multimodality Management for B ...... age C Hepatocellular Carcinoma

@ast

Multimodality Management for B ...... age C Hepatocellular Carcinoma

@en

Multimodality Management for B ...... age C Hepatocellular Carcinoma

@nl

type

label

Multimodality Management for B ...... age C Hepatocellular Carcinoma

@ast

Multimodality Management for B ...... age C Hepatocellular Carcinoma

@en

Multimodality Management for B ...... age C Hepatocellular Carcinoma

@nl

prefLabel

Multimodality Management for B ...... age C Hepatocellular Carcinoma

@ast

Multimodality Management for B ...... age C Hepatocellular Carcinoma

@en

Multimodality Management for B ...... age C Hepatocellular Carcinoma

@nl

P1433

Q26797643-B83D4B62-6E10-4C43-B13C-6D2CD55C4A73

P1476

Q26797643-8F0BF056-8ED5-420E-9006-0EB5BD2CF05D

P2093

Q26797643-0A1C55C0-1490-4EC4-A410-D7185A178130

Q26797643-8DAF0265-15FC-4EAE-A836-DDF3699C687E

Q26797643-C0234FD3-C129-43A1-BA22-FF351D66300A

Q26797643-E6A57CAC-55CD-4DA8-A704-F049F22E20E2

Q26797643-F280093D-1E16-4BB2-B676-629D7253E910

P2860

Q26797643-017FECBC-F8A6-43CA-B71A-7C092B24EEEC

Q26797643-0732ED49-35F8-453D-80EF-9A9C5226A084

Q26797643-0D852166-0E5C-4E94-B9A5-B032516D51C5

Q26797643-1D317A14-4087-45A8-8F8F-E7B0A68E97D5

Q26797643-1F336BF1-2992-4845-9126-2C83531DD0F8

Q26797643-1F88692B-3EC5-4487-A458-99E3FEE32E2B

Q26797643-1FB05D74-6385-403C-B89E-5E7821E70785

Q26797643-247F3A43-2D99-4E48-A525-C53E3380515B

Q26797643-28CB312E-A2BA-4FD4-94AB-2AFDF4452498

Q26797643-34043F6D-B166-432C-A11D-4CBD35742FBF

P304

Q26797643-31726097-BC92-4209-848A-E3AB1AE7515A

P31

Q26797643-84853D1F-6ABE-4739-8D66-B9BDE0FF6CA7

P356

Q26797643-EE4E4D2E-D182-4013-BBF2-2EF0577B3F05

P407

Q26797643-AF81757B-157C-4774-BC3A-AE2D4BA4EFA7

P433

Q26797643-2B0164E6-1940-469B-8433-AB833B1C3B1E

P478

Q26797643-F322B972-D056-4509-9CD5-9F2F58E90CC1

P50

Q26797643-27130BA1-152F-453B-AFB1-5C003427ECAB

P577

Q26797643-E6CB8769-B77B-4550-9FCA-2C626143A52F

P698

Q26797643-CFB8D248-8B2D-40E2-A4A5-EC0EC06A837A

P932

Q26797643-9004A5B6-C898-434D-8DAB-C469E851086D

P356

P1433

P1476

Multimodality Management for B ...... age C Hepatocellular Carcinoma

@en

P2093

Chihwan Choi

http://www.w3.org/2001/XMLSchema#string

Gi Hong Choi

http://www.w3.org/2001/XMLSchema#string

Jinsil Seong

http://www.w3.org/2001/XMLSchema#string

Mao-Bin Meng

http://www.w3.org/2001/XMLSchema#string

Masatoshi Tanaka

http://www.w3.org/2001/XMLSchema#string

P2860

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

Sorafenib in advanced hepatocellular carcinoma

Management of HCC

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma.

Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization.

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.

Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

P304

405-416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000343861

http://www.w3.org/2001/XMLSchema#string

P407

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26280002

http://www.w3.org/2001/XMLSchema#string

P932

4531424

http://www.w3.org/2001/XMLSchema#string